Which blood thinner should you take?

UNITED STATES: The study, published in the Annals of Internal Medicine, indicated that apixaban is related to gastrointestinal (GI) bleeding less frequently than other DOACs.

Dr Marcus stated that the persuasive evidence supporting apixaban in this observational analysis is consistent with what had been intuitively deduced from randomized trials of each specific DOAC against warfarin. The study did not involve Dr Gregory Marcus, a professor of medicine at the University of California, San Francisco.

Dr Gregg C. Fonarow, a cardiologist at UCLA Health in California, expressed his reservations about the study to MNT. This new observational study utilizes electronic healthcare databases from five nations. The treatment assignment was not randomized, making the outcome analyses susceptible to residual measurable and unmeasured confounding and selection biases.

Direct oral anticoagulants can be prescribed to persons with atrial fibrillation to reduce the risk of stroke, a common illness complication. According to a new observational study, one of these medications, apixaban, is associated with a lower incidence of gastrointestinal bleeding and a frequent anticoagulant side effect.

The study examined four DOACs and showed that they are equally efficient at preventing stroke, making them crucial for individuals with atrial fibrillation. Patients with atrial fibrillation who are candidates for oral anticoagulation have demonstrated in clinical studies that DOACs are superior to warfarin anticoagulation.